Ragnhammar, P. (1996) Anti-Tumoral Effect of GM-CSF with or without Cytokines and Monoclonal Antibodies in Solid Tumors. Medical Oncology, 13, 167-176.
https://doi.org/10.1007/BF02990844

has been cited by the following article:

• TITLE: Expression and Clinical Value Analysis of CSF2RA in Malignant Tumor Based on Database

  AUTHORS: Fengling Chen

  KEYWORDS: CSF2RA, GM-CSF, Cancer, Immune Cells

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.9 No.4, April 25, 2021

  ABSTRACT: Objective: to explore the expression and clinical value of CSF2RA in pan-cancer. Methods: the data was extracted from ONCOMINE, Human Protein Atlas and Kaplan Meier-plotter. The expression level of CSF2RA on cancer tissues and normal tissues, the relationship between CSF2RA and overall survival of cancer patients were analyzed, respectively. Results: CSF2RA mRNA was over-expressed on breast cancer, colorectal cancer, kidney cancer and liver cancer, and CSF2RA protein was over-expressed on melanoma. The expression level of CSF2RA was not associated with overall survival of cancer patients significantly. Conclusion: CSF2RA is over-expression on certain cancers and most immune cells, which maybe contributes to activation of immune system. The high expression of CSF2RA protein on melanoma is maybe associated with adverse outcome of application of GM-CSF.